Alexandria Real Estate Equities, Inc. (ARE)

Alexandria Real Estate Equities' stock price has experienced a notable decline in the past six months. As of June 20, 2025, the share price was $71.37, representing a 39.53% decrease from $118.03 on June 24, 2024. The company's first-quarter 2025 earnings report released around April 28, 2025, significantly impacted the stock. Alexandria reported a net loss of $11.6 million for Q1 2025, a substantial shift from a nearly $167 million profit in Q1 2024. The company significantly cut its guidance for full-year 2025. Despite these financial headwinds, the company maintained strong operational metrics in Q1 2025, including 91.7% occupancy for North American properties and robust leasing activity.

Demand for Alexandria Real Estate Equities' properties is generally event-driven rather than strictly seasonal, often tied to major clinical milestones. While there can be slight temporary declines in occupancy due to factors like seasonal increases in utilities, these expenses are typically recoverable from tenants. The company's operating results benefit from contractual annual rent escalations averaging approximately 3%. Demand for sophisticated lab space in major U.S. markets has been consistently high, amplified by events like the pandemic, indicating a consistent underlying demand.

Alexandria Real Estate Equities, Inc. (ARE) is a real estate investment trust (REIT) specializing in laboratory and office spaces for the life science, agtech, and technology industries. Founded in 1994, Alexandria pioneered the life science real estate niche and is recognized as the leading REIT exclusively dedicated to life science and technology campuses. The company creates collaborative "Megacampus" ecosystems in urban innovation clusters and provides strategic capital through Alexandria Venture Investments. As of March 31, 2025, Alexandria's asset base included 39.6 million rentable square feet (RSF) of operating properties and 4.0 million RSF of Class A/A+ properties under construction. Its client base comprises approximately 750 tenants.

Alexandria Real Estate Equities has a significant market presence in key life science innovation cluster locations across North America, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. The company's properties are strategically located near top academic institutions. The largest portion of its revenue was derived from Greater Boston (36%), followed by the San Francisco Bay Area (23%) and San Diego (16%).

Alexandria Real Estate Equities has maintained a strong brand reputation, being named one of the Most Trustworthy Companies in America by Newsweek for the third consecutive year. The company has received recognition for operational excellence in leasing, design, development, and asset management. They earned a San Francisco Business Times 2024 Real Estate Deals of the Year Award for a significant long-term lease with Vaxcyte, Inc. The company received two BOMA TOBY Awards in the Life Science category. Alexandria maintained a high tenant collection rate of 99.9% for Q1 2025 and achieved a tenant retention rate of over 80% in the past five years. The company is recognized for its commitment to sustainability, with several projects LEED certified.

Alexandria Real Estate Equities, Inc. has a diverse ownership base primarily dominated by large institutional investors. As of March 31, 2025, there were 753 institutional holders holding a total of 165,199,219 shares. As of June 20, 2025, 1343 institutional owners and shareholders had filed 13D/G or 13F forms with the SEC, holding a total of 171,793,504 shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Approximately 42.84% of the company's stock is owned by Institutional Investors, while 1.13% is owned by Insiders, and 28.83% by Public Companies and Individual Investors. Retail investors hold approximately 27.21% of the stock.